Plain-English translation of NCT07708779 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small Phase 1 study testing whether , a medicine used to treat tuberculosis, can be given safely by inhalation (through a nebulizer, like a breathing treatment) at higher doses than previously tried. Researchers want to see if getting the medicine directly into your lungs as a mist could work better than taking it by mouth, especially for tuberculosis that is resistant to standard treatment.
Tuberculosis that resists standard medicines is a growing problem worldwide. When the medication is inhaled directly into the lungs, it can reach much higher concentrations right where the infection is, which might work even against resistant strains. This approach could help stop the spread of tuberculosis faster and help patients get better more quickly.
You likely qualify if…
You likely don't qualify if…
You would visit the research center on different days to inhale the medication through a nebulizer (a machine that turns liquid medicine into a fine mist you breathe in). On separate days, you would receive three different doses: 200 mg, 600 mg, and 1200 mg. The researchers will monitor how your lungs respond and measure how much medicine reaches your bloodstream to make sure it is safe.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
Netherlands